1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

Ophthalmology Therapeutics Market to 2018 - Dosing Convenience and Cost-effectiveness

This report provides insights into the global ophthalmology therapeutics market, with forecasts until 2018.

FOR IMMEDIATE RELEASE

 
PRLog (Press Release) - Oct. 11, 2012 - The global Diabetic Macular Edema (DME) market will expand massively in the near future as a result of lifestyle changes and the introduction of more effective (and more expensive) treatments, says the latest report from pharmaceutical industry experts GBI Research.

According to their new research*, the business intelligence providers expect the global DME market to climb exponentially in value, from $43m in 2011 to a far greater $985m in 2018, exhibiting a Compound Annual Growth Rate (CAGR) of 57%.

Such dramatic growth is primarily attributed to the entrance of key treatments, including Novartis’s Lucentis, which gained approval from the European Commission early last year and the US Food and Drug Administration (FDA) this year.

These approval decisions were backed by data from two Novartis-funded clinical trials,  RESTORE and RESOLVE, that demonstrated that Lucentis was superior in visual acuity gain versus sham (dummy therapy) or laser therapy – the current standard of care.

For Sample Pages, please click or add the below link to your browser:
http://www.gbiresearch.com/RequestSamplePages.aspx?ID=Oph...

Global DME market growth is predicted to be further supported by Alimera’s Iluvien and Allergan’s Ozurdex. The former gained European approval in June, and will be available for commercial launch by the end of the year, but was rejected by the FDA late last year over safety concerns. Ozurdex, a promising biodegradable implant, is expected to receive FDA approval in 2015.

The global ophthalmology market as a whole is expected to perform far less impressively than its DME portion, primarily due to the impending patent expiries of prostaglandin analogs used in the treatment of glaucoma.

Global industry revenue will climb, however modestly, from $10 billion in 2011 to $12 billion in 2018, at a CAGR of 2.8%.

This report provides insights into the global ophthalmology therapeutics market, with forecasts until 2018.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.

GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets.

For further details, please click or add the below link to your browser:
http://www.gbiresearch.com/Report.aspx?ID=Ophthalmology-T...
Visit our report store: http://www.gbiresearch.com
For more details contact:
pressreleases@gbiresearch.com            
North America:                   +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

--- End ---

Click to Share

Contact Email:
***@gbiresearch.com Email Verified
Source:GBI Research
Phone:+914066166782
Address:John Carpenter House, John Carpenter Street,
:London, EC4Y 0AN
Zip:EC4Y 0AN
City/Town:London - London - United Kingdom
Industry:Health
Tags:, ,
Shortcut:http://prlog.org/11996926
Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...

Upcoming Press Releases...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
8.4K1.9K2.6K
Click to Share